Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock

On March 3, 2021 Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, reported that its Board of Directors has declared a quarterly cash dividend payment on the Company’s 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock") (Press release, Avid Bioservices, MAR 3, 2021, View Source [SID1234576005]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The quarterly dividend on the Series E Preferred Stock is payable on April 1, 2021 to holders of record at the close of business on March 15, 2021.

The quarterly dividend payment on the Series E Preferred Stock will be $0.65625 per share, which is equivalent to an annualized 10.50% per share, based on the $25.00 per share stated liquidation preference, accruing from January 1, 2021 through March 31, 2021. The Series E Preferred Stock is listed on the NASDAQ Capital Market and trades under the ticker symbol "CDMOP".

Amgen Announces 2021 Second Quarter Dividend

On March 3, 2021 Amgen (NASDAQ:AMGN) reported that its Board of Directors declared a $1.76 per share dividend for the second quarter of 2021 (Press release, Amgen, MAR 3, 2021, View Source [SID1234576004]). The dividend will be paid on June 8, 2021, to all stockholders of record as of the close of business on May 17, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Janux Therapeutics Announces $56 Million Series A to Advance Novel Cancer Drug Candidates using T Cell Engager (TRACTr) Technology

On March 3, 2021 Janux Therapeutics reported the close of a $56 million Series A financing led by Avalon Ventures and joined by new investors, OrbiMed and RA Capital Management, as well as existing investors, Bregua and Correlation Ventures (Press release, Janux Therapeutics, MAR 3, 2021, View Source [SID1234576003]). In conjunction with the financing, Peter Thompson, M.D., partner at OrbiMed, and Jake Simson, Ph.D., partner at RA Capital Management will join the Board of Directors. Janux’s proprietary Tumor Activated T Cell Engager (TRACTr) technology is designed to overcome specific limitations of current T cell immuno-oncology therapies. The financing will be used to advance the Company’s preclinical pipeline, including a TROP2-TRACTr and PSMA-TRACTr, with expected advancement of the Company’s first candidate into the clinic in the first half of next year.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to close this financing round with a top-tier investor syndicate who recognize the potential of our TRACTr technology to engineer best-in-class T cell engagers to provide better outcomes for cancer patients," said David Campbell, Ph.D., President and CEO of Janux Therapeutics. "With this financing, we’re focused on advancing our deep pipeline of T cell engager immunotherapies for the treatment of various cancers. We anticipate that the first of several development candidates will be entering the clinic next year for a solid tumor indication."

T cell engagers are an emerging class of immunotherapies that bind to a tumor cell and recruit a patient’s T cells to eradicate tumor cells. Although previous therapies utilizing other technologies have displayed substantial anti-tumor efficacy, they have been constrained by dose-limiting toxicities, poor pharmacokinetic profiles, and attenuated efficacy. Janux’s TRACTr technology is designed to overcome these limitations by integrating tumor-specific activation with crossover pharmacokinetics to produce best-in-class T cell engager therapeutics. In preclinical studies, Janux TRACTr drug candidates have demonstrated comparable anti-tumor efficacy relative to standard T cell engagers but lack the associated liabilities related to cytokine release, healthy tissue toxicities, or systemic immune activation.

"T cells are the most potent killers of tumor cells within the immune system, but directing, controlling, and integrating that activity is the key to next generation immunotherapies," said Jay Lichter, Ph.D., managing partner of Avalon Ventures. "Janux’s TRACTr technology offers the potential to balance T cell potency with specificity with the goal of generating immunotherapies with optimal safety, efficacy, and specificity."

Cardiff Oncology to Present at H.C. Wainwright Global Life Sciences Conference

On March 3, 2021 Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, pancreatic cancer, castrate-resistant prostate cancer and leukemias, reported that the Company will present at the upcoming H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021 (Press release, Cardiff Oncology, MAR 3, 2021, View Source [SID1234576002]). The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7 a.m. ET on Tuesday, March 9, 2021. The Company will also participate in one-on-one meetings with investors during the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Study Shows IP-001 to Amplify Tumoricidal and Immune Effect of Cancer Ablation Therapies

On March 3, 2021 Immunophotonics reported that A paper recently published in Cells has described how Immunophotonics’ immune-stimulating drug IP-001 was shown to be effective against metastatic tumors when combined with different forms tumor ablation (Press release, Immunophotonics, MAR 3, 2021, View Source [SID1234576001]). In this review, the authors briefly discuss the current applications of local ablation for cancer treatment and the effects of IP-001 in combination with other ablation therapies, a therapeutic approach that is pioneering the field of Interventional Immuno-Oncology (IIO).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!